CrystalGenomics Announces Positive Phase IIa Results For Osteoarthritis Study Of CG100649

CrystalGenomics, Inc. (Seoul, Korea) and CG Pharmaceuticals, Inc. (Emeryville, CA) announced positive results from a Phase IIa osteoarthritis (OA) study of the efficacy and safety of a next-generation NSAID, CG100649. The CG100649 treatment group met the primary efficacy endpoint by demonstrating a clinically and statistically significant change in the WOMAC(TM) OA score from baseline to Day 21 (p=0.010) compared to placebo. The study also met all key secondary endpoints, with the high dose demonstrating clinically and statistically significant superiority in the WOMAC(TM) OA score over the entire 21-day active treatment period (p=0.009) and in the WOMAC(TM) subscales of pain, stiffness and physical function (p=0.016, p=0.023, p=0.010, respectively) over the entire 35-day treatment and follow-up evaluation periods. Weekly pain relief scores showed statistically significant improvements at Days 7, 14, 21, and 28 (p